Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)
Gespeichert in:
| Veröffentlicht in: | Blood 2013-08, Vol.122 (6), p.1087-1088 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1088 |
|---|---|
| container_issue | 6 |
| container_start_page | 1087 |
| container_title | Blood |
| container_volume | 122 |
| creator | Greiner, Jochen Schneider, Vanessa Schmitt, Michael Götz, Marlies Döhner, Konstanze Wiesneth, Markus Döhner, Hartmut Hofmann, Susanne |
| description | |
| doi_str_mv | 10.1182/blood-2013-04-496844 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1419341365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120560163</els_id><sourcerecordid>1419341365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-69389745d1c14295b80d04d43891301bf3b359166f22eec482bac6d8fe7341203</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0EotPCGyDkZVkEji_JOBukqoJSaQosYG059smMURIH2ynq6_CkOJ2BJSvr-PwX2R8hrxi8ZUzxd90Qgqs4MFGBrGTbKCmfkA2ruaoAODwlGwBoymbLzsh5Sj8AmBS8fk7OuGh5q4TakN-347hMSCOmOUwJEzV746eUaT4gHZdsMrqy3fsw0dBT-5DDPJg0muwt_fz1jtHR7w-Z2jDl6LslI83h0dyb-xBNNyC1g5-8NQMNS7ZhxDXo6m5H5xKCU070l8-HU9jaWLoSvVznMr55QZ71Zkj48nRekO8fP3y7_lTtvtzcXl_tKitB5apphWq3snbMMsnbulPgQDpZbpkA1vWiE3XLmqbnHNFKxTtjG6d63ArJOIgLcnnMnWP4uWDKevTJ4jCYCcOSNJOsLUrR1EUqj1IbQ0oRez1HP5r4oBnolY5-pKNXOhqkPtIpttenhqUb0f0z_cVRBO-PAizvvPcYdbLlhyw6H9Fm7YL_f8MfQBaiDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1419341365</pqid></control><display><type>article</type><title>Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Greiner, Jochen ; Schneider, Vanessa ; Schmitt, Michael ; Götz, Marlies ; Döhner, Konstanze ; Wiesneth, Markus ; Döhner, Hartmut ; Hofmann, Susanne</creator><creatorcontrib>Greiner, Jochen ; Schneider, Vanessa ; Schmitt, Michael ; Götz, Marlies ; Döhner, Konstanze ; Wiesneth, Markus ; Döhner, Hartmut ; Hofmann, Susanne</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2013-04-496844</identifier><identifier>PMID: 23929838</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cancer Vaccines - immunology ; CD8-Positive T-Lymphocytes - immunology ; Cell Nucleus - metabolism ; Cytoplasm - metabolism ; Epitopes - immunology ; Humans ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - immunology ; Mutation ; Nuclear Proteins - genetics ; Nuclear Proteins - immunology ; Peptides - immunology ; Prognosis ; Stem Cell Transplantation ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Blood, 2013-08, Vol.122 (6), p.1087-1088</ispartof><rights>2013 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-69389745d1c14295b80d04d43891301bf3b359166f22eec482bac6d8fe7341203</citedby><cites>FETCH-LOGICAL-c408t-69389745d1c14295b80d04d43891301bf3b359166f22eec482bac6d8fe7341203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23929838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greiner, Jochen</creatorcontrib><creatorcontrib>Schneider, Vanessa</creatorcontrib><creatorcontrib>Schmitt, Michael</creatorcontrib><creatorcontrib>Götz, Marlies</creatorcontrib><creatorcontrib>Döhner, Konstanze</creatorcontrib><creatorcontrib>Wiesneth, Markus</creatorcontrib><creatorcontrib>Döhner, Hartmut</creatorcontrib><creatorcontrib>Hofmann, Susanne</creatorcontrib><title>Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)</title><title>Blood</title><addtitle>Blood</addtitle><subject>Cancer Vaccines - immunology</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cell Nucleus - metabolism</subject><subject>Cytoplasm - metabolism</subject><subject>Epitopes - immunology</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - immunology</subject><subject>Mutation</subject><subject>Nuclear Proteins - genetics</subject><subject>Nuclear Proteins - immunology</subject><subject>Peptides - immunology</subject><subject>Prognosis</subject><subject>Stem Cell Transplantation</subject><subject>Survival Analysis</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1DAUhi0EotPCGyDkZVkEji_JOBukqoJSaQosYG059smMURIH2ynq6_CkOJ2BJSvr-PwX2R8hrxi8ZUzxd90Qgqs4MFGBrGTbKCmfkA2ruaoAODwlGwBoymbLzsh5Sj8AmBS8fk7OuGh5q4TakN-347hMSCOmOUwJEzV746eUaT4gHZdsMrqy3fsw0dBT-5DDPJg0muwt_fz1jtHR7w-Z2jDl6LslI83h0dyb-xBNNyC1g5-8NQMNS7ZhxDXo6m5H5xKCU070l8-HU9jaWLoSvVznMr55QZ71Zkj48nRekO8fP3y7_lTtvtzcXl_tKitB5apphWq3snbMMsnbulPgQDpZbpkA1vWiE3XLmqbnHNFKxTtjG6d63ArJOIgLcnnMnWP4uWDKevTJ4jCYCcOSNJOsLUrR1EUqj1IbQ0oRez1HP5r4oBnolY5-pKNXOhqkPtIpttenhqUb0f0z_cVRBO-PAizvvPcYdbLlhyw6H9Fm7YL_f8MfQBaiDg</recordid><startdate>20130808</startdate><enddate>20130808</enddate><creator>Greiner, Jochen</creator><creator>Schneider, Vanessa</creator><creator>Schmitt, Michael</creator><creator>Götz, Marlies</creator><creator>Döhner, Konstanze</creator><creator>Wiesneth, Markus</creator><creator>Döhner, Hartmut</creator><creator>Hofmann, Susanne</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130808</creationdate><title>Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)</title><author>Greiner, Jochen ; Schneider, Vanessa ; Schmitt, Michael ; Götz, Marlies ; Döhner, Konstanze ; Wiesneth, Markus ; Döhner, Hartmut ; Hofmann, Susanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-69389745d1c14295b80d04d43891301bf3b359166f22eec482bac6d8fe7341203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Cancer Vaccines - immunology</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cell Nucleus - metabolism</topic><topic>Cytoplasm - metabolism</topic><topic>Epitopes - immunology</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - immunology</topic><topic>Mutation</topic><topic>Nuclear Proteins - genetics</topic><topic>Nuclear Proteins - immunology</topic><topic>Peptides - immunology</topic><topic>Prognosis</topic><topic>Stem Cell Transplantation</topic><topic>Survival Analysis</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greiner, Jochen</creatorcontrib><creatorcontrib>Schneider, Vanessa</creatorcontrib><creatorcontrib>Schmitt, Michael</creatorcontrib><creatorcontrib>Götz, Marlies</creatorcontrib><creatorcontrib>Döhner, Konstanze</creatorcontrib><creatorcontrib>Wiesneth, Markus</creatorcontrib><creatorcontrib>Döhner, Hartmut</creatorcontrib><creatorcontrib>Hofmann, Susanne</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greiner, Jochen</au><au>Schneider, Vanessa</au><au>Schmitt, Michael</au><au>Götz, Marlies</au><au>Döhner, Konstanze</au><au>Wiesneth, Markus</au><au>Döhner, Hartmut</au><au>Hofmann, Susanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2013-08-08</date><risdate>2013</risdate><volume>122</volume><issue>6</issue><spage>1087</spage><epage>1088</epage><pages>1087-1088</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23929838</pmid><doi>10.1182/blood-2013-04-496844</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2013-08, Vol.122 (6), p.1087-1088 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1419341365 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Cancer Vaccines - immunology CD8-Positive T-Lymphocytes - immunology Cell Nucleus - metabolism Cytoplasm - metabolism Epitopes - immunology Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - immunology Mutation Nuclear Proteins - genetics Nuclear Proteins - immunology Peptides - immunology Prognosis Stem Cell Transplantation Survival Analysis Transplantation, Homologous Treatment Outcome |
| title | Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T16%3A25%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20responses%20against%20the%20mutated%20region%20of%20cytoplasmatic%20NPM1%20might%20contribute%20to%20the%20favorable%20clinical%20outcome%20of%20AML%20patients%20with%20NPM1%20mutations%20(NPM1mut)&rft.jtitle=Blood&rft.au=Greiner,%20Jochen&rft.date=2013-08-08&rft.volume=122&rft.issue=6&rft.spage=1087&rft.epage=1088&rft.pages=1087-1088&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2013-04-496844&rft_dat=%3Cproquest_cross%3E1419341365%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1419341365&rft_id=info:pmid/23929838&rft_els_id=S0006497120560163&rfr_iscdi=true |